Who Will Build the Systems to Oversee Clinical AI? ↗
An editorial connection between questions, not a claim that the studies demonstrate the same mechanism or outcome.
Frontier Science · TOPIC v1
Can measuring brain function help us choose an antidepressant?
Which differences in treatment response do measured differences between patients represent?
Read article → Can measuring brain function help us choose an antidepressant?
2026-09-23 09:08:41.974 UTC · Last recorded update
CURRENT READING
In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
Recorded editorial state, not a maturity score
- Historical dataRecorded
- Prospective trialRecorded
- Selection utilityUnverified
- ReplicationUnverified
New question opened · v1
Published the analysis and recorded the next checks.
Permanent link to this revision ↗01 / WHAT WE TRACK
Which differences in treatment response do measured differences between patients represent?
02 / EVIDENCE & TECHNOLOGY
Resting-state fMRI / cognitive tasks / clinical prediction
03 / EDITORIAL READING
Which differences in treatment response do measured differences between patients represent?
04 / WHAT REMAINS UNKNOWN
The result concerns the utility of these models for treatment selection, not the impossibility of fMRI-based or personalized care.
05 / NEXT CHECK
Drug comparisons at the same treatment stage, and separate validation of early changes to inform subsequent decisions.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDFunctional changes after treatment starts may help reach decisions sooner when pretreatment prediction alone is insufficient.
What would change our view: Reconsider if prospective comparisons in other populations do not reproduce improved decisions or patient benefit.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTURESMART-D ↗
Which differences in treatment response do measured differences between patients represent?
Related questions, optional follows
Map ↗Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor ↗
Contrasts fMRI-based response prediction with identifying an autoimmune treatment target.
Looking across diseases for drugs that treat fibrosis ↗
The physiological biomarker study of antidepressants and fibrosis models differ in disease and measurement method. They share the question of what must be established before a measurable difference can guide treatment selection.
Evidence: NIH / NCATS ↗www.nature.com ↗
ACE levels are lower. Which functions have changed? ↗
Keep the psychosis ACE study distinct from depression biomarkers while comparing what connects a measurable difference to treatment selection or molecular function.
Latest card updates
Latest 5 · editorial record dates- v1 · 2026-09-23 09:08:41.974 UTCNew question opened
Published the analysis and recorded the next checks.
Reading at the time: In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Background readings
Source dates and verification scope
原著論文 ↗
www.nature.com · accessed 2026-09-23 · public-source
セルトラリンの処方情報 ↗
dailymed.nlm.nih.gov · accessed 2026-09-23 · public-source
ブプロピオンの処方情報 ↗
dailymed.nlm.nih.gov · accessed 2026-09-23 · public-source
トランスポーターの機能調節を調べた研究 ↗
pubmed.ncbi.nlm.nih.gov · accessed 2026-09-23 · public-source
先行研究 ↗
pmc.ncbi.nlm.nih.gov · accessed 2026-09-23 · public-source
fMRI信号と神経活動を比較した基礎研究 ↗
pubmed.ncbi.nlm.nih.gov · accessed 2026-09-23 · public-source